← Studies & programmes
Emerging treatmentsPhase 3 study in peopleEU authorised

Cenrifki (tolebrutinib): EU-authorised treatment for a defined secondary progressive MS group

EU-authorised indication: Adults with secondary progressive multiple sclerosis without relapses in the previous two years

Published by MyelinWatch:

Tolebrutinib / Cenrifki

In plain words

A medicine taken by mouth, authorised in the European Union for some adults with a form of multiple sclerosis that gradually worsens (secondary progressive) and no relapses for two years. In a large study, people taking it had a lower risk of disability worsening than with a placebo. It can harm the liver, so a doctor experienced in the condition prescribes and monitors it; availability in Greece is not confirmed.

What is the approach?

Tolebrutinib is an oral inhibitor of Bruton’s tyrosine kinase (BTK), a signalling protein in immune cells. The approach aims to reduce inflammatory activity in MS, including processes linked to disability progression; it has not been shown to restore myelin.

Approach source: EMA — Cenrifki medicine overview ↗

What is being studied

Tolebrutinib is an oral drug that blocks Bruton’s tyrosine kinase (BTK), an enzyme involved in immune-cell signalling. The Phase 3 HERCULES study compared it with placebo in people with secondary progressive MS without relapses. Cenrifki is the medicine name under which tolebrutinib is authorised in the EU for adults with secondary progressive MS who have had no relapses in the previous two years. Sanofi also tested tolebrutinib in primary progressive MS (Phase 3 PERSEUS, against placebo) and in relapsing MS (Phase 3 GEMINI 1 and 2, against teriflunomide, an MS medicine taken by mouth).

Research stage

Phase 3 study in people

EU-authorised for adults with SPMS without relapses in the previous two years; HERCULES completed; PERSEUS in primary progressive MS did not meet its main goal

What we know so far

HERCULES randomised 1,131 people. Its peer-reviewed report found a lower risk of disability progression confirmed for at least six months with tolebrutinib than with placebo (hazard ratio 0.69; 95% confidence interval 0.55–0.88). The study is completed and results are posted in the official registry. The EMA identifies liver injury as the main safety concern; liver tests are required before and during treatment, and the medicine is under additional monitoring. In relapsing MS, the peer-reviewed GEMINI report found tolebrutinib not superior to teriflunomide in reducing the yearly relapse rate (0.13 versus 0.12 in GEMINI 1, with 974 participants; 0.11 versus 0.11 in GEMINI 2, with 899). In a pooled analysis, disability worsening confirmed for at least six months occurred in 8.3% versus 11.3% (hazard ratio 0.71; 95% confidence interval 0.53–0.95), but this comparison was not formally tested and does not prove a benefit. Minor bleeding, such as tiny skin bleeds and heavy menstrual periods, was more common with tolebrutinib. Sanofi describes GEMINI as supporting data for the EU authorisation. In primary progressive MS, Sanofi announced on 15 December 2025 that PERSEUS did not meet its main goal; it gave no figures and will not seek approval for that form of MS. On 24 December 2025 Sanofi announced that the US Food and Drug Administration (FDA) had issued a complete response letter, meaning it did not approve the application for non-relapsing secondary progressive MS at that time; this page does not establish the current US status.

What this means for patients today

The EU marketing authorisation is real but applies only to the stated adult SPMS group. It does not by itself establish whether Cenrifki is commercially available or reimbursed in Greece. Treatment requires a prescription and supervision by a doctor experienced in MS; the liver precautions are part of the authorised use. This is not evidence that the medicine restores myelin or cures MS. The EU indication does not cover relapsing MS or primary progressive MS: in those studies tolebrutinib was not better than teriflunomide at reducing relapses, or did not meet its main goal.

Treatment or approach
Cenrifki (tolebrutinib) • oral BTK inhibitor authorised in the EU for a defined SPMS population
How it is intended to work
Oral Bruton’s tyrosine kinase (BTK) inhibitor
Where the study is running
EU-wide authorisation; Greek commercial availability and reimbursement not established by the cited sources
Source: European Medicines Agency — official EMA medicine record ↗Source: New England Journal of Medicine — original HERCULES trial, PMID 40202696 ↗ Source: ClinicalTrials.gov — HERCULES NCT04411641, completed with results posted ↗ Source: New England Journal of Medicine — GEMINI 1 and 2 trials, PMID 40202623 ↗ Source: Sanofi — PERSEUS result in primary progressive MS, 15 December 2025 ↗ Source: ClinicalTrials.gov — PERSEUS NCT04458051, completed, no results posted ↗ Source: Sanofi — EU approval announcement naming GEMINI 1 and 2 as supporting data, 23 June 2026 ↗ Source: Sanofi — US FDA complete response letter for non-relapsing SPMS, 24 December 2025 ↗
Published by MyelinWatch
Last substantive MyelinWatch update

Programme updates — newest research developments first

  1. EU marketing authorisation issued on 19 June 2026Research event/source date:

    Cenrifki: EU authorises tolebrutinib for a defined secondary progressive MS group

    The EMA record states that Cenrifki (tolebrutinib) received EU-wide marketing authorisation on 19 June 2026 for adults with secondary progressive multiple sclerosis who have had no relapses in the previous two years. This is the authorisation date, separate from the earlier CHMP opinion and later company announcements. In the Phase 3 HERCULES trial, 1,131 people were randomised to tolebrutinib or placebo; the peer-reviewed report found a lower risk of disability progression confirmed for at least six months with tolebrutinib (hazard ratio 0.69; 95% confidence interval 0.55–0.88).

    Source: European Medicines Agency — official EMA medicine record ↗Source: New England Journal of Medicine — original HERCULES trial, PMID 40202696 ↗ Source: ClinicalTrials.gov — HERCULES NCT04411641, completed with results posted ↗

  2. Completed Phase 3 study in people; company-reported main result, no full results postedResearch event/source date:

    Tolebrutinib: Phase 3 PERSEUS study in primary progressive MS did not meet its main goal

    On 15 December 2025, Sanofi announced that its Phase 3 PERSEUS study (NCT04458051) of tolebrutinib in primary progressive multiple sclerosis (MS) did not meet its main goal: tolebrutinib was not shown to delay the time to disability progression confirmed over six months, compared with placebo. That measure combines worsening on the EDSS disability scale, a timed 25-foot walk and a hand-dexterity test. The registry lists 767 participants; according to Sanofi, people aged 18 to 55 were assigned two to one to daily tolebrutinib tablets or placebo for up to about five years. Sanofi said that the preliminary safety profile was consistent with earlier tolebrutinib studies and that drug-induced liver injury is an identified risk of the drug. Based on these results, Sanofi said it will not seek regulatory approval of tolebrutinib for primary progressive MS. The announcement gives no figures. On 11 November 2026, ClinicalTrials.gov listed the study as completed on 14 November 2025, with no results posted.

    Source: Sanofi — official company announcement ↗Source: ClinicalTrials.gov — PERSEUS NCT04458051, completed, no results posted ↗ Source: EU Clinical Trials Information System — PERSEUS 2024-514495-41-00, ended ↗